Feasibility of a prostaglandin-timolol fixed combination first-line treatment of primary glaucoma

Glaucoma is the most common cause of irreversible blindness worldwide. The reasons for the high and growing level of blindness due to glaucoma are low diagnostic population coverage, the incorrect hypotensive therapy and low glaucoma patient’s adherence. In practice, the recommended initial monotherapy does not allow achieving target IOP at moderate and advanced glaucoma with a high IOP level, which, according to clinical guidelines, is an indication for the initial combination therapy. Starting with a latanoprost-timolol fixed combination allows achieving a significant IOP decrease and increasing patient compliance by optimizing the number of instillations, reducing the total treatment cost, the total preservative volume, the absence of a washout effect and waiting between instillation of two drugs.